AURKA and pancreatic ductal adenocarcinoma: For instance, clinical trials evaluating the potential efficacy of targeting necroptosis in metastatic solid cancer (NCT04739618) and assessing the clinical efficacy of Aurora kinase A (AURKA), a negative regulator of necrosome activation, inhibitors in pancreatic ductal adenocarcinoma (NCT04479306, NCT04555837, NCT04085315 and NCT01924260) are underway.